Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis - PubMed
3 hours ago
- #antidiabetic drugs
- #pharmacovigilance
- #erectile dysfunction
- Erectile dysfunction is a significant complication in diabetic patients, but drug-induced sexual dysfunction from antidiabetic drugs is underrecognized.
- The study used FDA Adverse Event Reporting System (FAERS) data to analyze erectile dysfunction reports linked to common antidiabetic drugs.
- Significant disproportionality signals were found for semaglutide, sitagliptin, and dapagliflozin, indicating increased reporting of erectile dysfunction.
- Time-to-onset analysis suggests erectile dysfunction occurs randomly over treatment, requiring continuous monitoring rather than just early intervention.
- Other drugs like dulaglutide, linagliptin, and metformin did not show significant safety signals for erectile dysfunction.
- The findings are preliminary and do not establish causality; further research is needed to confirm true drug-related risks.
- Clinicians should consider discussing sexual health with male patients using these antidiabetic medications.